What happened
Korea Pharma reported separate results for FY2025: revenue of US$59.2M (+7.8% year on year), an operating loss of US$600K (from a profit a year earlier) and a net loss of US$1.78M (from a profit a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$59.2M |
|---|---|
| Revenue vs a year earlier | +7.8% |
| Operating profit | −US$600K |
| Net income | −US$1.78M |
| Period | FY2025 (separate) |
| Filed | 2026-03-06, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260306901335 → open original filing |
Source: DART. Information only, not investment advice.